Abstract
Thromboembolic disorders are still the leading causes of morbidity and mortality in developed societies. Therefore, prophylaxis and treatment of arterial and venous thrombosis are among the main therapeutic challenges nowadays. Simultaneous action on several targets involved in pathology of thrombosis offers potential advantages compared to existing drugs which were developed as selective modulators of single targets. The review focuses on dual inhibitors of coagulation enzymes, dual antiaggregatory compounds exerting their action on different combinations of platelet targets, as well as on anticoagulant/antiaggregatory compounds which interfere with at least one target involved in blood coagulation and at least one target engaged in the process leading to platelet aggregation.
Keywords: Anticoagulants, antiplatelet, antithrombotics, dual inhibitors, multitarget drugs, prophylaxis, anticoagulant/antiaggregatory compounds, haemostasis, antiplatelet activity, antiaggregatory drugs, calcium ions, coagulation factors, pharmacokineticproperties, predictable pharmacokinetics, thromboxane synthase
Current Topics in Medicinal Chemistry
Title: Multitarget Antithrombotic Drugs
Volume: 11 Issue: 22
Author(s): Milos Ilic, Danijel Kikelj and Janez Ilas
Affiliation:
Keywords: Anticoagulants, antiplatelet, antithrombotics, dual inhibitors, multitarget drugs, prophylaxis, anticoagulant/antiaggregatory compounds, haemostasis, antiplatelet activity, antiaggregatory drugs, calcium ions, coagulation factors, pharmacokineticproperties, predictable pharmacokinetics, thromboxane synthase
Abstract: Thromboembolic disorders are still the leading causes of morbidity and mortality in developed societies. Therefore, prophylaxis and treatment of arterial and venous thrombosis are among the main therapeutic challenges nowadays. Simultaneous action on several targets involved in pathology of thrombosis offers potential advantages compared to existing drugs which were developed as selective modulators of single targets. The review focuses on dual inhibitors of coagulation enzymes, dual antiaggregatory compounds exerting their action on different combinations of platelet targets, as well as on anticoagulant/antiaggregatory compounds which interfere with at least one target involved in blood coagulation and at least one target engaged in the process leading to platelet aggregation.
Export Options
About this article
Cite this article as:
Ilic Milos, Kikelj Danijel and Ilas Janez, Multitarget Antithrombotic Drugs, Current Topics in Medicinal Chemistry 2011; 11 (22) . https://dx.doi.org/10.2174/156802611798184364
DOI https://dx.doi.org/10.2174/156802611798184364 |
Print ISSN 1568-0266 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4294 |
Call for Papers in Thematic Issues
Chemistry Based on Natural Products for Therapeutic Purposes
The development of new pharmaceuticals for a wide range of medical conditions has long relied on the identification of promising natural products (NPs). There are over sixty percent of cancer, infectious illness, and CNS disease medications that include an NP pharmacophore, according to the Food and Drug Administration. Since NP ...read more
Current Trends in Drug Discovery Based on Artificial Intelligence and Computer-Aided Drug Design
Drug development discovery has faced several challenges over the years. In fact, the evolution of classical approaches to modern methods using computational methods, or Computer-Aided Drug Design (CADD), has shown promising and essential results in any drug discovery campaign. Among these methods, molecular docking is one of the most notable ...read more
Drug Discovery in the Age of Artificial Intelligence
In the age of artificial intelligence (AI), we have witnessed a significant boom in AI techniques for drug discovery. AI techniques are increasingly integrated and accelerating the drug discovery process. These developments have not only attracted the attention of academia and industry but also raised important questions regarding the selection ...read more
From Biodiversity to Chemical Diversity: Focus of Flavonoids
Flavonoids are the largest group of polyphenols, plant secondary metabolites arising from the essential aromatic amino acid phenylalanine (or more rarely from tyrosine) via the phenylpropanoid pathway. The flavan nucleus is the basic 15-carbon skeleton of flavonoids (C6-C3-C6), which consists of two phenyl rings (A and B) and a heterocyclic ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Immune-Neuroendocrine Interactions Involving Thymus and Pineal Gland in Stem Cell Therapy of Age-Related Diseases
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Adenosine Myocardial Perfusion Imaging
Current Medical Imaging Resveratrol and Clinical Trials: The Crossroad from In Vitro Studies to Human Evidence
Current Pharmaceutical Design Ozone: A Multifaceted Molecule with Unexpected Therapeutic Activity
Current Medicinal Chemistry Impact of Matrix Metalloproteinases on Atherosclerosis
Current Drug Targets Changes in Serum Amino Acids in Migraine Patients without and with Aura and their Possible Usefulness in the Study of Migraine Pathogenesis
CNS & Neurological Disorders - Drug Targets Prevention of Contrast Induced Nephropathy
Current Drug Therapy Hypertriglyceridaemia, Postprandial Lipaemia and Non-HDL Cholesterol
Current Pharmaceutical Design Non-Covalent Binding of Disodium Disuccinate Astaxanthin to the Catalytic Site of Phosphodiesterase 5A: A Molecular Modeling Study
Letters in Drug Design & Discovery New Developments on Thromboxane and Prostacyclin Modulators Part I: Thromboxane Modulators
Current Medicinal Chemistry Stem-cell-based Therapies for Improving Islet Transplantation Outcomes in Type 1 Diabetes
Current Diabetes Reviews Cerebrovascular Ultrasonography for Selecting Patients for Stroke Intervention
Recent Patents on CNS Drug Discovery (Discontinued) Infants and Children with Tachycardia: Natural History and Drug Administration
Current Pharmaceutical Design Prostaglandin E<sub>2</sub> Receptor 4 (EP4): A Promising Therapeutic Target for the Treatment of Cancer and Inflammatory Diseases
Current Chemical Biology Reduction of Sympathetic Hyperactivity by Agents that Inhibit the Renin Angiotensin Aldosterone System
Current Hypertension Reviews Polyphenols as Potential Therapeutics for Pain and Inflammation in Spinal Cord Injury
Current Molecular Pharmacology B-Type Natriuretic Peptide for Diagnosis and Therapy
Recent Patents on Cardiovascular Drug Discovery Reactive Oxygen Species, Vascular Disease and Cardiovascular Surgery
Current Vascular Pharmacology p38 Mitogen-Activated Protein Kinase: A Critical Node Linking Insulin Resistance and Cardiovascular Diseases in Type 2 Diabetes Mellitus
Endocrine, Metabolic & Immune Disorders - Drug Targets Reactive Oxygen Species in Vascular Wall
Cardiovascular & Hematological Disorders-Drug Targets